Researchers Refute Proposed Neuron Migration Pathway

A team of scientists was unable to replicate controversial, high-profile findings published in 2011.

By | January 11, 2017

FLICKR, NICHDIn April 2011, Amparo Acker-Palmer  of Goethe University in Frankfurt and colleagues published a study in Nature that identified key features of the Reelin signaling pathway, which is linked to epilepsy, schizophrenia, and Alzheimer’s disease. Immediate concerns were raised, and Nature published a corrigendum in September. But the notice failed to fully address their concerns, so Joachim Herz and colleagues at the University of Texas Southwestern Medical Center decided to repeat the experiment themselves. Last November, they and a few colleagues published (also in Nature) their failed attempt to do so.

“Our recent report in Nature now highlights these inconsistencies,” Herz told Retraction Watch. “Please note, however, that several of the major inconsistencies were noted independently by numerous colleagues throughout the world, giving rise to a lively online discussion.”

In the September 2011 correction notice, the authors stated that mistakes with the images and labels did not affect the study’s conclusions—that ephrin B proteins bind to Reelin in the mammalian brain to regulate neuronal migration—and even claimed to have repeated the experiment in an additional cohort of animals with “exactly the same results.” But Herz and colleagues were unable to reproduce the findings in a series of knockout mouse experiments. They outline their wrok in a Brief Communication Arising published in Nature last November. In the same issue, Acker-Palmer and colleagues argue that Herz’s team used different methods and poor analyses.

Herz told Retraction Watch: “[T]he extent and the degree of the discrepancies not only over a single data point, but over multiple different genotypes, anatomy and biochemistry is too great to be dismissed with this kind of handwaving. . . . If the dependence of the Reelin pathway on Eph/Ephrin signaling during migration were as absolute as [Acker-Palmer’s team] reported, we should have seen at least partial penetrance of their phenotype in our models.”

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham